For patients with terminal cancer, chemotherapy does not improve quality of life
the ONA take:
Chemotherapy administered to patients with cancer who are near death does not improve quality of life and may even reduce quality of life in those who have good performance status, a recent study published in JAMA Oncology has shown.
For the study, researchers evaluated 312 patients with terminal cancer who were estimated to live no more than 6 months. The majority were receiving chemotherapy. Results showed that patients with a poor performance status who received chemotherapy achieved no improvement in quality of life during their final week prior to death.
Moreover, researchers found that in those with a good performance status, treatment worsened their quality of life compared with patients with a good performance status who were not receiving treatment.
Current American Society of Clinical Oncology (ASCO) guidelines contend that patients with terminal cancer and a good performance status are the most likely to benefit from chemotherapy, but these findings suggest that chemotherapy given to patients at the end of life may be wasteful, unnecessary, and potentially harmful.
Chemotherapy administered to patients with cancer who are near death does not improve quality of life.
- Cholesterol-Lowering Drugs May Prevent Breast Cancer Recurrence
- Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
- Some Early Breast Cancer Patients Should Have Breast Conservation Instead of Mastectomy
- BBD Regimen Efficacious as First-line Therapy for Myeloma
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Nut Consumption Inversely Associated With Lung Cancer Risk
- Targeting AR Mutations Promising in Metastatic Prostate Cancer
- GUCS 2017: Early Immunotherapy Discontinuation in mRCC
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Myalgia-arthralgia Syndrome Associated With Taxanes in Patients with Breast Cancer
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|